enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Vaginal introital laxity - Wikipedia

    en.wikipedia.org/wiki/Vaginal_introital_laxity

    During childbirth, women are more likely to develop vaginal introital laxity, eventually leading to the weakening of pelvic floor muscles and may develop urinary symptoms such as OAB. [ 7 ] Vaginal introital laxity may also weaken the support structures around the urethra , which is the tube that helps carry urine outside of the body from the ...

  3. Overactive bladder - Wikipedia

    en.wikipedia.org/wiki/Overactive_bladder

    Overactive bladder (OAB) is a common condition where there is a frequent feeling of needing to urinate to a degree that it negatively affects a person's life. [2] The frequent need to urinate may occur during the day, at night , or both. [ 4 ]

  4. Oxybutynin - Wikipedia

    en.wikipedia.org/wiki/Oxybutynin

    Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder.It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time.

  5. AOL Mail

    mail.aol.com

    Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!

  6. Nikki Giovanni, prolific poet and civil rights activist, dies ...

    www.aol.com/nikki-giovanni-prolific-poet-civil...

    Yolande Cornelia "Nikki" Giovanni Jr., the internationally recognized poet and provocateur, died Monday in Blacksburg, Virginia. She was 81. Giovanni was a prolific writer, activist, educator ...

  7. Fesoterodine - Wikipedia

    en.wikipedia.org/wiki/Fesoterodine

    Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). [2] It was approved by the European Medicines Agency in April 2007, [3] the US Food and Drug Administration on October 31, 2008 [4] and Health Canada on February 9, 2012.

  8. Mortgage and refinance rates for Jan. 6, 2025: Average rates ...

    www.aol.com/finance/mortgage-and-refinance-rates...

    Average mortgage rates are edging down moderately week over week of Monday, January 6, 2024, though remain at elevated levels for benchmark 30-year and 15-year fixed terms, this despite three back ...

  9. Solabegron - Wikipedia

    en.wikipedia.org/wiki/Solabegron

    A Phase II study of solabegron for overactive bladder (OAB) looked at 258 patients with moderate-to-severe incontinence experiencing an average of 4.5 wet episodes per day. Results demonstrated a statistically significant improvement with solabegron as compared with placebo, as measured by the percentage reduction of the number of wet episodes ...